natgillin/translations-raw huggingface dataset:
A procedure according to claim 1, characterized in that said first seam (15) is inwardly recessed at a distance sufficient to substantially make the edges of the mattress panel (1') coincide with the outer edges of the folded gusset. 
Postupak prema zahtjevu 1, naznačen time što je prvi šav (15) okrenut prema unutra na udaljenosti dovoljnoj da u biti načini da se rubovi obloge madraca (1’) podudaraju s vanjskim rubovima presavijenog ušitka.
A procedure according to claim 1, characterized in that the part of the edge of the mattress panel (1') external to said first seam (15) is able to rise with respect to the remainder of the mattress panel. 
Postupak prema zahtjevu 1, naznačen time što se dio ruba obloge madraca (1’) koji je vanjski u odnosu na prvi šav (15) može podići u odnosu na ostatak obloge madraca.
A procedure according to claim 1, characterized in that said gusset is made by coupling mattress lining fabric with a backing material such as a fabric, a nonwoven, PVC or polyurethane. 
Postupak prema zahtjevu 1, naznačen time što se ušitak radi tako da se spoji tkanina madraca s potpornim materijalom kao što je tkanina, netkani materijal, PVC ili poliuretan.
A procedure according to claim 5, characterized in that said coupling is achieved by means of adhesives or flame, or ultrasound or stitching. 
Postupak prema zahtjevu 5, naznačen time što se spajanje postiže pomoću adheziva ili plamena, ili ultrazvukom ili šivanjem.
stitching the outer edge of a first part (10) of the folded gusset to the edge of the mattress panel (1'); 
šivanje vanjskog ruba prvog dijela (10) presavijenog ušitka za rub obloge madraca (1’);
stitching the outer edge of the second part (11) of the folded gusset to the edge of the side band (2); 
šivanje vanjskog ruba drugog dijela (11) presavijenog ušitka za rub bočne trake (2);
guiding and folding means (23) suitable for cooperating with said sewing machine, and for preparing said gusset (14') folded lengthwise into two parts and positioning it ready folded on the edge of the mattress panel (1') internal to the mattress cover, to enable the stitching the gusset onto the mattress panel, along said first seam (15) inwardly recessed from the edge of the mattress panel, in correspondence with said fold dividing the gusset into two parts. 
vodilice i sredstva za presavijanje (23) prikladni za suradnju sa šivaćim strojem, i za pripremu ušitka (14’) koji je po dužini presavijen na dva dijela, i njegovo postavljanje na rub obloge madraca (1’) s unutarnje strane presvlake madraca, radi omogućavanja šivanja ušitka na oblogu madraca, duž prvog šava (15) okrenutog prema unutra od ruba obloge madraca, što odgovara mjestu gdje mjesto presavijanja dijeli ušitak na dva dijela;
said sewing machine (20) being suitable for completing said first seam (15) by passing through the full thickness of said mattress panel (1'). 
šivaći stroj (20) prikladan je za završetak prvog šava (15) prolazeći punom debljinom obloge madraca (1’).
an arm (24) hinged at one end (25) to the body of said sewing machine (20) at a given distance from a needle (22) on the sewing machine; 
ručicu (24) na jednom kraju (25) zakrivljenu prema šivaćem stroju (20) na zadanoj udaljenosti od igle (22) na šivaćem stroju;
a feeding and folding means (26), suitable for carrying and folding the gusset (14), placed at the opposite end of said arm (24) in a position facing said needle (22), and comprising: 
sredstva za uvođenje i savijanje (26), prikladna za nošenje i presavijanje ušitka (14), postavljena na suprotni kraj ručice (24) u položaju koji gleda prema igli (22), a obuhvaćaju:
a hollow saddle (27) capable of sliding or shuffling along a guide (28) attached to the sewing machine flatbed, in the vicinity of said needle (22), so that said saddle can be juxtaposed with said needle by turning said arm (24); 
šuplje sedlo (27) koje može kliziti ili se vući duž vodilice (28) spojene na postolje šivaćeg stroja, u blizini igle (22), tako da sedlo može doći u dodir s iglom okretanjem ručice (24);
The engine (100) of claim 5, wherein the engine (100) is operable such that the crossover valve (150) is open during a combustion event in the expansion cylinder (104). 
Motor (100) iz patentnog zahtjeva 5, naznačen time što radi tako da je zaobilazni ventil (150) otvoren za vrijeme izgaranja u ekspanzijskom cilindru (104).
a fuel injection system operable to add fuel to the exit end of the crossover passage (114). 
sustav injiciranja goriva koji radi tako da dodaje gorivo u izlazni kraj zaobilazne cijevi (114).
an exhaust valve (154) disposed over the expansion cylinder (104), the exhaust valve (154) being separate from the crossover passage (114). 
ispušni ventil (154) preko ekspanzijskog cilindra (104), a taj ispušni ventil je odvojen od zaobilazne cijevi (114).
A compound as claimed in claim-1, selected from among the following group: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz sljedeće skupine:
converting a compound of the formula (I) into another compound of the formula (I) 
prevođenju spoja formule (I) u drugi spoj formule (I)
removing any protecting groups; or 
uklanjanju bilo koje zaštitne skupine; ili
A compound of formula (I) as defined in any one of claims 1 to 8 for use for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof, for example an anxiety disorder, a cognitive disorder, or a neurodegenerative disorder, Alzheimer's disease or Parkinson's disease, attention deficit disorder or obsessive compulsive disorder, stroke or head trauma, eating disorder or obesity. 
Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je namijenjen upotrebi u liječenju poremećaja središnjeg živčanog sustava povezanog s ili pod utjecajem receptora 5-HT6 kodpacijenta kojem je to potrebno, primjerice anksioznog poremećaja, kognitivnog poremećaja ili neurodegenerativnog poremećaja, Alzheimerove bolesti ili Parkinsonova bolesti, poremećaja nedostatka pažnje ili opsesivno-kompulzivnog poremećaja, inzulta ili ozljede glave, poremećaja hranjenja ili pretilosti.
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and, an effective amount of a compound of formula (I) as defined in any one of claims 1 to 8. 
Farmaceutski pripravak, naznačen time što sadrži farmaceutski prihvatljivu podlogu i djelotvornu količinu spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 8.
Use of compound of formula (I), as defined in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor. 
Upotreba spoja formule (I), u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje poremećaja središnjeg živčanog sustava povezan s ili pod utjecajem receptora 5-HT6.
Identity document/bank card (1) comprising a number of interconnected layers and a number of authenticity features, including a perforation, provided in said layers, wherein a reinforcement layer (8) with threads extending near said perforation (3) is provided, characterized in that said perforations extend through said reinforcement layer. 
Osobna isprava/bankovna kartica koja ima više slojeva koji su međusobno povezani, pri čemu osobna isprava sadržava više karakteristika o vjerodostojnosti i uključuje perforaciju koja je predviđena u navedenim slojevima, pri čemu je predviđen i jedan sloj za pojačanje (8) s vlaknima, koja vlakna se pružaju uz navedene perforacije, naznačena time što se navedene perforacije pružaju kroz navedeni sloj za pojačanje.
Method according to one of the preceding claims, characterised in that the video recorder (1) is at least connected to the server (3) on every recording or deleting event at the personal video recorder (1) and/or periodic, particularly after a settable period. 
Postupak temeljem jednog od prethodnih zahtjeva, naznačen time da je video snimač (1) barem spojen na server (3) prilikom svakog snimanja ili brisanja na osobnom video snimaču (1) i/ili periodički, naročito nakon perioda namještanja.
Method according to one of the preceding claims, characterised in that the mobile equipment (5) is identified by using the Mobile Subscriber Integrated Services Digital Network Number (MSISDN). 
Postupak temeljem jednog od prethodnih zahtjeva, naznačen time da se mobilni uređaj (5) identificira koristeći Digitalni Mrežni Broj Mobilnog Pretplatnika Integriranih Usluga (MSISDN).
A process for the preparation of a pharmaceutical composition as defined in claim 1, which comprises preparing a mixture of lisinopril dihydrate, sodium carboxymethyl amylopectin and microcrystalline cellulose with the absence of a calcium salt of phosphoric acid, granulating said mixture with water, drying the wet granulated mass in vacuo at a product temperature below 35-40 °C, homogenizing the dry blend obtained with amlodipine besilate, sodium carboxymethyl amylopectin and microcrystalline cellulose, then mixing the blend with magnesium stearate and compressing the mixture obtained into tablets or filling it into capsules. 
Postupak proizvodnje farmaceutskog sastava koji je određen u zahtjevu 1, naznačen time, da obuhvaća pripremanje mješavine lizinopril dihidrata, natrijevog karboksimetil amilopektina i mikrokristalinične celuloze u odsustvu kalcijeve soli fosforne kiseline, granuliranje spomenute mješavine s vodom, sušenje vlažne granulirane mase u vakuumu na temperaturi proizvoda ispod 35 – 40 °C, homogeniziranje dobivene suhe smjese amlodipin besilatom, natrijavim karboksimetil amilopektinom i mikrokristaliničnom celulozom, zatim mješanje smjese sa magnezij stearatom i sabijanje dobivene smjese u tablete ili punjenje iste u kapsule.
Use of a G protein-coupled receptor for identifying GIP secretagogues, in an in vitro method comprising the steps of: 
Uporaba receptora vezanih G-proteina za identifikaciju GIP sekretogoga, na način in vitro, naznačena time, da se sastoji od sljedećih koraka:
wherein the ability of the test compound to stimulate functionality of the receptor is indicative of the test compound being a GIP secretagogue. 
pri čemu sposobnost test spoja za stimulaciju djelotvornosti receptora pokazuje da li je test spoj postao GIP sekretogog.
contacting a compound which stimulates functionality of the receptor in step (b) in vitro with a vertebrate enteroendocrine cell or a cell capable of secreting GIP; and 
stavljanje u doticaj spoja koji stimulira djelotvornost receptora iz koraka (b) in vitro sa enteroendokrinom stanicom kralježnjaka ili sa stanicom sposobnom za GIP sekreciju;
determining whether the compound increases a GIP level in a vertebrate, by measuring the GIP level in a sample obtained from a vertebrate previously administered with a compound which stimulates functionality of the receptor in step (b); 
određivanje da li spoj povećava GIP razinu kod kralježnjaka, mjerenjem GIP razine u uzorku dobivenom od kralježnjaka na kojemu je prethodno primijenjen spoj koji stimulira djelotvornost receptora iz koraka (b);
Use according to any one of claims 1 to 14, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO:2. 
Uporaba prema bilo kojem zahtjevu od 1 do 14, naznačena time, da receptor sadrži sekvencu amino kiseline receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2.
contacting a GPR119 agonist in vitro with a vertebrate enteroendocrine cell or a cell capable of secreting GIP; and 
stavljanje u doticaj agonista GPR119 in vitro sa enteroendokrinom stanicom kralježnjaka ili stanice sposobne za GIP sekreciju; i
contacting a test compound with a host cell or with membrane of a host cell comprising a G protein-coupled receptor, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: amino acids 1-335 of SEQ ID NO:2; 
stavljanje u doticaj test spoja sa stanicom domaćina ili s membranom stanice domaćina, koji sadrži receptor vezanih G-proteina, pri čemu receptor vezanih G-proteina sadrži sekvencu amino kiseline odabranu iz skupine koja sadrži: amino kiseline 1-335 od SEQ ID NO:2;
determining the ability of the test compound to stimulate functionality of the receptor; 
određivanje sposobnosti test spoja da stimulira djelotvornost receptora;
wherein the ability of the test compound to stimulate functionality of the receptor is indicative of the test compound being a GIP secretagogue, and wherein the GPR119 agonist of step (a) is a test compound identified as stimulating functionality of the receptor in step y. 
pri čemu sposobnost test spoja da stimulira djelotvornost receptora, pokazuje da li je test spoj postao GIP sekretogog, i pri čemu agonist GPR119 iz koraka (a) je test spoj identificiran kao stimulator djelotvornosti receptora u koraku (y).
The method of any one of claims 57 to 67, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO:2. 
Postupak prema bilo kojem zahtjevu od 57 do 67, naznačen time, da receptor sadrži sekvencu amino kiseline receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2.
Use of a G protein-coupled receptor for identifying GIP secretagogues, in an in vitro method comprising the steps of: 
Uporaba receptora vezanih G-proteina, naznačena time, da služi za identifikaciju GIP sekretogoga, postupkom in vitro koji obuhvaća sljedeće korake:
contacting a G protein-coupled receptor with an optionally labeled known ligand to the receptor in the presence or absence of a test compound, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of: 
stavljanje u doticaj receptora vezanih G-proteina sa opcijski obilježenim poznatim ligandom za receptor u prisutnosti ili u odsutnosti test spoja, pri čemu receptor vezanih G-proteina sadrži sekvencu amino kiseline odabranu iz skupine koja sadrži:
the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1; the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO:2;; 
sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su hibridizirani pod uvjetima visoke oskudice prema dodatku od SEQ ID NO:1; sekvencu amino kiseline od receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2;
the amino acid sequence of a constitutively active version of a G protein-coupled receptor having SEQ ID NO:2; and 
sekvencu amino kiseline od tvorbene aktivne verzije receptora vezanih G-proteina koja ima SEQ ID NO:2; i
determining whether less of said complex is formed in the presence of the test compound than in the absence of the test compound; 
određivanje da li je formirano manje spomenutog kompleksa u prisutnosti test spoja nego li u odsutnosti test spoja.
contacting a compound in the presence of which less of said complex is formed in step (c) in vitro with a vertebrate enteroendocrine cell or a cell capable of secreting GIP; and 
stavljanje u doticaj onoga spoja u čijoj je prisutnosti formirano manje kompleksa u koraku (c) in vitro sa enteroendokrinom stanicom kralježnjaka ili sa stanicom sposobnom za GIP sekreciju; i
Use according to any one of claims 43 to 54, wherein the receptor comprises the amino acid sequence of a G protein-coupled receptor having at least about 80% identity to SEQ ID NO:2. 
Uporaba prema bilo kojem zahtjevu od 43 do 54, naznačena time, da receptor sadrži sekvencu amino kiseline od receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2.
the amino acid sequence of a G protein-coupled receptor encoded by a polynucleotide hybridizing under conditions of high stringency to the complement of SEQ ID NO:1; the amino acid sequence of a G protein-coupled receptor having at least about 80% identitiy to SEQ ID NO:2; 
sekvencu amino kiseline od receptora vezanih G-proteina kodiranu s polinukleotidima koji su hibridizirani pod uvjetima visoke oskudice prema dodatku od SEQ ID NO:1; sekvencu amino kiseline od receptora vezanih G-proteina koja ima najmanje oko 80% identiteta od SEQ ID NO:2;
determining whether less of said complex is formed in the presence of the test compound than in the absence of the test compound; 
određivanje da li je manje spomenutog kompleksa formirano u prisutnosti test spoja nego li u odsutnosti test spoja;
decarboxylation to obtain pentamethylene-glutarimide; 
dekarboksilacija radi dobivanja pentametilen-glutarimida;
A process according to claim 3 wherein step a) is carried out by addition of a,a'-diaminocarbonyl-β,β-pentamethylene glutarimide to a sodium hydroxide solution and bringing to reflux. 
Postupak prema zahtjevu 3, naznačen time što se korak a) provodi dodavanjem a,a’-diaminokarbonil-β,β-pentametilen glutarimida u otopinu natrijevog hidroksida i dovođenjem do refluksa.
A process according to claim 3 wherein step b) is carried out by addition of a solution of hydrochloric acid at a portion of the solution obtained from step a), heating, formation of a suspension and addition of the remaining solution obtained from step a). 
Postupak prema zahtjevu 3, naznačen time što se korak b) provodi dodavanjem otopine klorovodične kiseline dijelu otopine dobivene u koraku a), zagrijavanjem, formiranjem suspenzije i dodavanjem preostale otopine dobivene u koraku a).
A process according to claim 3 wherein step c) is carried out by addition of a sodium hydroxide solution, bringing to reflux and precipitating the product by addition of hydrochloric acid. 
Postupak prema zahtjevu 3, naznačen time što se korak c) provodi dodavanjem otopine natrijevog hidroksida, dovođenjem do refluksa i taloženjem produkta pomoću dodavanja klorovodične kiseline.
A process according to claim 10 wherein the product precipitation is carried out in the presence of a precipitation co-solvent. 
Postupak prema zahtjevu 10, naznačen time što se taloženje produkta provodi u prisutnosti dodatnog otapala za taloženje.
The child-resistant blister pack (1) as claimed in claim 1, wherein the first and second lines of weakness (5a, 5b) are perpendicular to each other. 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da su prva i druga crta sa smanjenim otporom (5a, 5b) okomite jedna na drugu.
The child-resistant blister pack (1) as claimed in claim 1, wherein the third set of lines or weakness (9) forms a triangle at the internal corner (11) of each unit package region (2). 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da treća skupina crta sa smanjenim otporom (9) tvori trokut na unutarnjem kutu (11) svakog područja za pakiranje pojedinačnih doza (2).
The child-resistant blister pack (1) as claimed in claim 1, wherein the third set of lines of weakness (9a) forms a curve at the internal corner (11) of each unit package region (4a). 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da treća skupina crta sa smanjenim otporom (9a) tvori zavoj na unutarnjem kutu (11) svakog područja za pakiranje pojedinačnih doza (4a).
The child-resistant blister pack (1) as claimed in claim 1, wherein the pack (1) comprises at least four unit package regions (2, 4a). 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da pakiranje (1) sadrži najmanje četiri područja za pakiranje pojedinačnih doza (2, 4a).
The child-resistant blister pack (1) as claimed in claim 1, wherein the blister film sheet (7) is opaque. 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da je tankoslojna blister folija (7) neprozirna.
The child-resistant blister pack (1) as claimed in claim 1, wherein the blister film sheet (7) is transparent. 
Blister pakiranje koje djeca ne mogu otvoriti (1) kako se navodi u patentnom zahtjevu 1, naznačeno time, da je tankoslojna blister folija (7) prozirna.
The device set forth in claim 2 which also includes a damper valve (30) adapted to control the flow of cooling air from said section box (20) to said air plenum (48). 
Uređaj u skladu s patentnim zahtjevom 2, naznačen time što on ima osim toga i jedan prigušni ventil (30) koji je prilagođen za to, da regulira strujanje zraka za hlađenje od navedenog profilnog kućišta (20) prema navedenom razdjelniku za zrak (48).
The device set forth in claim 13 or 14 wherein the damper valve (30) is carried by the air plenum (48) and is axially adjustable relative to the section box (20). 
Uređaj u skladu s patentnim zahtjevom 13 ili 14, naznačen time što je prigušni ventil (30) nošen od razdjelnika za zrak (48) i što se može namještati u odnosu na profilno kućište (20).
The method of claim 16 or 17 wherein said air plenum (48) is adjustable carried on said section box (20) and which also includes the step of adjusting the position of the air plenum relative to the section box. 
Postupak u skladu s patentnim zahtjevom 16 ili 17, naznačen time što je navedeni razdjelnik za zrak (48) postavljen na navedeno profilno kućište (20) na takav način da se može podešavati i što osim toga obuhvaća i fazu koja omogućava namještanje položaja razdjelnika za zrak u odnosu na profilno kućište.
A compound according to any one of claims 1-19, or a pharmaceutically acceptable salt thereof, for use in the treatment of a colorectal cancer, a head and neck cancer, a pancreatic cancer, a breast cancer, a gastric cancer, a bladder cancer, a vulvar cancer, a leukemia, a lymphoma, a melanoma, a renal cell carcinoma, an ovarian cancer, a brain cancer, an osteosarcoma, or a lung cancer. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća.
A method for producing or multiplying seed of a conditionally male sterile Brassica napus line with the genotype MsMsrfrf, said method comprising the steps of 
Postupak za proizvodnju ili umnažanje sjemena uvjetovane muške sterilne linije Brassica napus s genotipom MsMsrfrf, a navedeni se postupak sastoji od koraka
predominantly male sterile when exposed before and/or during flowering to a temperature of less than 28°C, and 
dominantno muška sterilna kad je izložena prije i/ili tijekom cvatnje na temperaturu manju od 28°C, i
exposing said conditionally male sterile Brassica napus plant for at least 4 hours to a temperature of higher than 35°C, and 
izlaganja navedene uvjetovane muške sterilne biljke Brassica napus tijekom najmanje 4 sata na temperaturu od više od 35°C, i
exposing the heat-treated conditionally male sterile Brassica napus plant obtained in step (b) to a temperature of less than 33°C until development of male fertile flowers, and 
izlaganja toplinski obrađene uvjetovane muške sterilne biljke Brassica napus dobivene u koraku (b) na temperaturu od manje od 33°C do razvoja muških plodnih cvjetova, i
allowing for self pollination of the Brassica napus plants having said male fertile flowers obtained in step (c), letting the seed develop, and harvesting the seed, wherein the harvested seeds are characterized in that they are seeds of a conditionally male sterile Brassica napus line with the genotype MsMsrfrf. 
dozvoljavanje samo oprašivanja biljaka Brassica napus koje imaju navedene muške plodne cvjetove dobivene u koraku (c), ostavljajući da se razvije sjeme, te žetve sjemena, pri čemu je sjeme koje se žanje naznačeno time da su sjemenke od uvjetovane muške sterilne linije Brassica napus s genotipom MsMsrfrf.
A method for producing seed of a conditionally male sterile Brassica napus line with the genotype Msmsrfrf, said method comprising the steps of 
Postupak za proizvodnju sjemena uvjetovane muške sterilne linije Brassica napus s genotipom Msmsrfrf, a navedeni se postupak sastoji od koraka